Introduction {#S1}
============

Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL) and in most cases runs an indolent course. However, approximately 20% of patients would progress to a widespread disease with multiple skin tumors and extracutaneous involvement with dire outcome ([@B1]). Male gender, young age, and folliculotropic subtype are risk factors for progression, but their predictive value is low ([@B1], [@B2]). There are currently no robust biomarkers that predict the course of the disease.

The tumor suppressor gene *TP53* is central in tumorigenesis and regarded as a master regulator of several signaling pathways involved in this process. *TP53* is mutated in more than 50--70% of all solid tumors and in approximately 10--20% in hematological malignancies ([@B3]). While low-grade lymphoid neoplasms reveal low p53 mutation rates, lymphomas and leukemias (in particular chronic lymphatic leukemia) with an aggressive clinical course demonstrate higher frequencies ([@B4]--[@B7]). To this end, a strong correlation was found between p53 functional status and clinical outcomes in lymphoma, such as mortality or resistance to chemotherapy ([@B8], [@B9]). *TP53* may be mutated in a proportion of patients with another type of CTCL, Sezary syndrome, but mutations are not predictive for the course of the disease ([@B10]). Less is known about *TP53* gene status in MF. Previous studies suggested that p53 overexpression and mutation is uncommon in early MF ([@B11]--[@B13]) but can be found in advanced stages indicating prognostic significance ([@B14], [@B15]). It has also been suggested that p53 mutations in MF are caused by ultraviolet radiation ([@B11], [@B14], [@B16]). Therefore, in this study we wished to elucidate the frequency and potential role of *TP53* mutations in MF according to disease stage and course. We have developed a method, which enables *TP53* sequencing from paraffin-embedded samples from a relatively large number of patient samples.

Materials and Methods {#S2}
=====================

Materials {#S2-1}
---------

In this retrospective study, we reviewed clinical data and histopathology of 157 patients diagnosed with MF in Denmark from 1980 to 2013 and registered in the Danish pathology registry database (Patobank) and The Danish Cutaneous Lymphoma Database.[^1^](#fn1){ref-type="fn"} The diagnosis was made by correlation between clinical findings and histological examination of skin biopsies ([@B17]). Staging was performed according to ISCL/EORTC criteria ([@B18]). Also, 30 patients had MF stage IIB or higher, and tissue for p53 analysis was available in 19 cases (Table [1](#T1){ref-type="table"}). Control materials included CTCL cell lines SeAx, MyLa200, and MF1885, together with biopsies from solid tumors with known p53 mutations ([@B19]).

###### 

**Patients with MF included in mutation analysis of *TP53***.

  No.   Gender/age (years)   Clinical stage   Mutation status of *TP53*                                                                                    Disease duration at highest stage
  ----- -------------------- ---------------- ------------------------------------------------------------------------------------------------------------ -----------------------------------
  1     Male/67              T3N3M1B0         Mutated: exon 4: c.100C \> T (p.P34S); exon 4: c.254C \> T (p.P85L); exon 4: c.430C \> T (p.Q144stop)        7 years, DOD
  2     Female/91            T3N0M0B0         Mutated: exon 8: c.811G \> A (p.E271K); exon 5 and 6 unable to amplify                                       1 year, DOD
  3     Female/67            T4N3M0B2         No mutations                                                                                                 10 years, DOD
  4     Male/72              T3N2M0B0         No mutations                                                                                                 2 years, AWD
  5     Female/89            T3N0M0B0         No mutations                                                                                                 8 years, DOC
  6     Female/56            T4N1M0B1         No mutations                                                                                                 5 years, DOD
  7     Male/69              T3N3M1B0         No mutations: exon 5 and 6 unable to amplify                                                                 3 years, DOD
  8     Male/76              T4N3M0B1a        No mutations                                                                                                 3 years, DOD
  9     Female/65            T3N1M0B0         No mutations                                                                                                 14 years, AWD
  10    Male/83              T3N0M0B0         No mutations                                                                                                 11 years, AWD
  11    Female/55            T3N0M0B0         No mutations                                                                                                 5 years, AWD
  12    Male/75              T3N0M0B0         No mutations in exon 7, 10: exon 4, 5, 6, 8, and 9 unable to amplify                                         3 years, DOC
  13    Male/64              T4N3M0B2         Mutated: exon 5: c.449C \> T (p.T150I)                                                                       4 years, DOD
  14    Female/74            T3N0M0B0         No mutations                                                                                                 6 years, AWD
  15    Female/71            T3N0M0B0         No mutations                                                                                                 12 years, AWD
  16    Female/63            T3N3M0B0         No mutations: exon 4, 5, and 6 unable to amplify                                                             5 years, DOC
  17    Male/76              T3N0M1B0         Mutated: exon 5: c. 502C \> T (p.H168Y); exon 5: c. 530C \> A (p.P178H); exon 6: c. 670G \> T (p.E224Stop)   3 years, DOD
  18    Male/99              T3N0M0B0         Mutated: exon 8: c.818G \> A (p.R273H)                                                                       2 years, DOC
  19    Male/66              T3N2M0B0         Mutated: exon 5: c.457C \> T (p.P153S); exon 5: c.461G \> A (p.G154D)                                        5 years, DOD

*AWD, alive with disease; DOD, dead of disease; DOC, dead of other causes*.

TP53 Sequencing {#S2-2}
---------------

Genomic DNA was extracted from 4 μm × 5 μm paraffin-embedded biopsies from lesional skin and purified using the DNA Sample Preparation Kit (Roche Life Science, Basel, Switzerland) according to the manufacturer's instructions. Concentration and purity was measured on a Nanodrop 2000 instrument. PCR amplification of *TP53* exon 4--10 is performed in five separate nested PCR reactions according to Table [2](#T2){ref-type="table"}. The primers are designed using Primer 3 software ([@B20], [@B21]) and purchased from MWG Eurofins.[^2^](#fn2){ref-type="fn"} The nest 1 reactions contained, in a volume of 15 μl, 0.33 μmol/l of each nest 1 primer, 7.5 μl RedEx PCR master mix (Sigma-Aldrich, St Louis, MO, USA) and 50--100 ng genomic DNA and was amplified using the following PCR conditions: initial denaturating at 95°C for 5 min, 25 cycles at 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s, and a final extension at 72°C for 10 min. The nest 2 reactions contained, in a volume of 50 μl, 0.4 μM of each nest 2 primer, 25 μl RedEx PCR master mix (Sigma-Aldrich) and 1 μl 100-fold diluted nest 1 product. The nest 2 PCR conditions were the same as for the nest 1 reactions except that a total of 35 cycles were used. All five nest 1 and nest 2 reactions uses the same amplification settings. The PCR products were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany). Sequence reactions were carried out using T3 and T7 primers, 25 ng purified PCR products, and BigDye Terminator 3.1 Cycle Sequencing Kit chemistry (Life Technologies, Carlsbad, CA, USA) for BigDye incorporation and were subsequently sequenced on an ABI3500DX DNA sequenator according to the manufacturer's instructions.

###### 

**Primer sequences for sequencing of *TP53* exon 4--10**.

  Exon           Primer sequence            Fragment (bp)
  ------- ------ -------------------------- ---------------
  4       F-N1   5′-CCATGGGACTGACTTTCTGC    534
          R-N1   5′-GAGGAATCCCAAAGTTCCAA    
          F-N2   5′-CTGGTAAGGACAAGGGTTGG    457
          R-N2   5′-AGAAATGCAGGGGGATACG     
  5 + 6   F-N1   5′-GGAGGTGCTTACGCATGTTT    588
          R-N1   5′-GGGAGGTCAAATAAGCAGCA    
          F-N2   5′-GCCGTCTTCCAGTTGCTTTA    506
          R-N2   5′-GCCACTGACAACCACCCTTA    
  7       F-N1   5′-CCTGCTTGCCACAGGTCT      294
          R-N1   5′-TGATGAGAGGTGGATGGGTAG   
          F-N2   5′-TGCTTGCCACAGGTCTCC      236
          R-N2   5′-GGTCAGAGGCAAGCAGAGG     
  8 + 9   F-N1   5′-GGGAGTAGATGGAGCCTGGT    486
          R-N1   5′-CCCCAATTGCAGGTAAAACA    
          F-N2   5′-GGGACAGGTAGGACCTGATTT   431
          R-N2   5′-AAGAAAACGGCATTTTGAGTG   
  10      F-N1   5′-TGCATGTTGCTTTTGTACCG    300
          R-N1   5′-GAAGGCAGGATGAGAATGGA    
          F-N2   5′-TGCATGTTGCTTTTGTACCG    263
          R-N2   5′-CCTAGGAAGGCAGGGGAGTA    

*The nest 2 primers contain T3 and T7 tags on F-N2 and R-N2, respectively*.

Statistical Analysis {#S2-3}
--------------------

The overall survival (time in years from the diagnosis to death of any cause or to the last observation) was calculated for all 30 patients with stage \>IIB MF. Cox logistic regression was performed using SPSS statistical package (version 22, IBM Corporation, Armonk, North Castle, NY, USA) using enter, forward, or backward methods. Kaplan--Meier plot was generated in SPSS to compare survival curves between patients with mutated and germline *P53. p* ≤ 0.05 was considered significant.

Results {#S3}
=======

In 6 out of 19 cases (31%), 1 or several mutations could be identified, exhibiting a heterogeneous pattern with mutations in different exons at various codon sites (Table [1](#T1){ref-type="table"}).

To investigate whether *TP53* mutations had impact on survival, we compared patients with mutated and normal *TP53* by Kaplan--Meier analysis. Because the sample size was small, we decided to compare survival of the 6 patients with mutated p53 to all 30 patients with stage \>IIB MF treated in our center in the same time frame (14 women, 16 men; mean age 71.8 years, SD 12.6). As shown in Figure [1](#F1){ref-type="fig"}, patients with mutated *TP53* had a shorter survival than the controls. The statistically significant difference (*p* = 0.05) was maintained when data were adjusted to age, stage, and gender by Cox logistic regression. Adjusted odds ratio for death in the presence of mutated *P53* was 2.99 (95% confidence interval 1.12--8.00, Cox regression) comparing to the control group.

![**Comparison of survival in MF patients with normal *TP53* (solid line) and mutated gene (broken line)**. Six patients with mutated *TP53* (Table [1](#T1){ref-type="table"}) are compared against the control group of 30 patients with stage IIB MF or higher. The difference in survival is significant (*p* = 0.05) after adjustment for stage, age, and gender by Cox logistic regression. *x*-axis -- years, *y*-axis -- probability of survival.](fmed-03-00051-g001){#F1}

Discussion {#S4}
==========

The protocol developed in this study allowed for PCR amplification and Sanger sequencing of *TP53* in archival formalin-fixed and paraffin-embedded samples of MF. Only in 4 out of 19 samples, we were unable to amplify one or several exons, which is most probably due to sample age and DNA crosslinking.

The frequency of mutations in stage IIB or higher was 31%, which is similar to what has been reported previously ([@B11], [@B16]). In contrast, no mutations have been identified in a recent study of McGirt et al. ([@B14]) who reported Pro72Arg polymorphism to be more common in MF. Mutation analysis did not reveal any distinctive pattern of alterations in *TP53*. None of the earlier reported mutations were identical to our findings, and our cases harbored only one of the known hotspot mutations (R273H in case 18). In a recent study, Choi et al. reported 7 different mutations located at different sites in 7 out of 40 analyzed patients, including the well-known R273H hotspot ([@B22]). Our cases revealed mainly missense single nucleotide mutations resulting in stop codons (cases 1 and 17). Frequent C \> T transitions seem to support the hypothesis that *TP53* mutations demonstrate an UV B signature, which might be related to the effect of phototherapy given repeatedly in the earlier stages of the disease ([@B11], [@B14], [@B16]).

*TP53* mutations seem to be associated with worse outcome (higher overall mortality). However, this analysis should be interpreted with caution since our sample is small, and the presence of mutations may reflect more intensive use of phototherapy in patients with aggressive, difficult to control disease. Larger sample and careful matching with the control patients with normal *TP53* status will be required to elucidate this issue.
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